Transient silencing of PTEN in human CD34 + cells enhances their proliferative potential and ability to engraft immunodeficient mice

  • Inho Kim
  • , Yoo Jin Kim
  • , Jean Yves Métais
  • , Cynthia E. Dunbar
  • , Andre Larochelle

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The ability to expand hematopoietic stem and progenitor cells (HSPCs) in vitro will enhance the success of a wide range of transplant-related therapies. PTEN (phosphatase and tensin homologue deleted on chromosome 10) has been implicated as a regulator of murine HSPC self-renewal, but little is understood about the role of PTEN in human HSPC regulation. We tested the impact of transient small interfering RNA (siRNA)-induced inhibition of PTEN expression in human CD34 + cells on their cell cycle profile, their susceptibility to retroviral transduction, and their ability to self-renew and repopulate nonobese diabetic/severe combined immunodeficiency disease with interleukin-2 receptor γ-chain deficiency mice. Reduced PTEN messenger RNA and protein levels were confirmed in PTEN siRNA-treated CD34 + cells compared with control siRNA-treated CD34 + cells. Transient silencing of PTEN in CD34 + cells promoted their entry into cell cycle, and increased their expansion in vitro compared with control siRNA-treated CD34 + cells. When these cells were transduced with retroviral vectors, transduction efficiencies in the bulk CD34 + cells transfected with PTEN siRNA were significantly higher compared with CD34 + cells transfected with a control siRNA. Transient PTEN suppression in CD34 + cells also increased their proliferation and engraftment potential in nonobese diabetic/severe combined immunodeficiency disease with interleukin-2 receptor γ-chain deficiency mice, and maintained their multilineage differentiation capacity in vivo. No mice developed myeloproliferative disorders or leukemias. Similar to findings with murine HSPC, PTEN may also promote quiescence of human HSPC. With optimization of technologies for transfer of siRNA in primary CD34 + cells, this approach may facilitate investigations into the mechanisms underlying HSPC self-renewal, and could find clinical applications in gene therapy protocols.

Original languageEnglish
Pages (from-to)84-91
Number of pages8
JournalExperimental Hematology
Volume40
Issue number1
DOIs
StatePublished - Jan 2012

Bibliographical note

Funding Information:
We thank Dr. David Stroncek and the Department of Transfusion Medicine staff for the apheresis and CD34 + cell selection from healthy donors. The gammaretrovirus vectors used in this study, MND.MFG.YFP c10 were a gift from Dr. Hans-Peter Kiem. We are also grateful to Keyvan Keyvanfar from the Hematology Branch flow facility for his assistance with flow sorting and analysis. This work was supported by the intramural research programs of the National Heart, Lunch, and Blood Institute (C.E.D.) of the National Institutes of Health.

Fingerprint

Dive into the research topics of 'Transient silencing of PTEN in human CD34 + cells enhances their proliferative potential and ability to engraft immunodeficient mice'. Together they form a unique fingerprint.

Cite this